Aducanumab – The Brand New Miracle Alzheimer’s Drug

 

‘I Felt Like the Drug Was Working’ First Patient Receives Biogen’s Alzheimer’s Drug in New Trial

Video taken from the channel: Being Patient Alzheimer’s


 

Howard Fillit, MD: Aducanumab Findings Lead the Way in Dementia

Video taken from the channel: Neurology Live


 

Aducanumab for Alzheimer’s

Video taken from the channel: Cleveland Clinic


 

Biogen to seek FDA approval for Alzheimer’s drug Aducanumab

Video taken from the channel: CNBC Television


 

New Alzheimer’s Drug: Is There Finally A Cure?!

Video taken from the channel: Max Lugavere


 

Clinical Trial Participant ‘Biogen’s Aducanumab Was Working’ | Patient Perspectives | Being Patient

Video taken from the channel: Being Patient Alzheimer’s


 

New Alzheimer’s drug to be submitted to FDA for approval

Video taken from the channel: Mayo Clinic


Trials have demonstrated aducanumab helps to untangle Alzheimer’s tell-tale protein clumps in the brain, potentially reversing the disease. The FDA has not considered a new treatment for the. Pharmaceutical giant Biogen submitted its controversial Alzheimer’s drug aducanumab to the FDA for approval on Wednesday morning, marking the latest twist in a dizzying saga and a potential.

Aducanumab is a monoclonal antibody, an expensive type of drug that attaches to specific proteins in order to disable them. The drug clears a key protein in Alzheimer’s disease — beta amyloid —. Aducanumab has been shown in clinical trials to slow cognitive-related issues caused by the onset of Alzheimer’s disease, Aducanumab has been shown in clinical trials to slow cognitive-related issues caused by the onset of Alzheimer’s diseas. The early trials show that high doses of aducanumab “significantly reduced amyloid plaques in the brain,” according to Alzheimers News Today. The drug provides new hope to the estimated 44 million people around the world who suffer from Alzheimer’s or related dementia, including more than 500,000 in Canada.

Biogen announced the completion of their regulatory filing to the U.S. Food and Drug Administration (FDA) on aducanumab, an anti-amyloid antibody for the treatment of. “Aducanumab is an antibody. It binds to the amyloid beta protein, especially aggregate forms of the amyloid beta protein that we consider to be the principle bad guys in Alzheimer’s disease. FDA Accepts Biogen’s BLA for Alzheimer’s Candidate Aducanumab Biogen (BIIB) said its BLA for aducanumab, the Alzheimer’s disease candidate it is.

Dec. 5, 2019 New study results about an experimental drug its maker claims can slow mental decline in Alzheimer’s disease patients were released Thursday. Studies on aducanumab. Aducanumab (BIIB037) is an investigational therapy from Biogen for treating Alzheimer’s disease..

The U.S. Food and Drug Administration (FDA) granted aducanumab priority review in August 2020. Neurimmune originally developed aducanumab.

After entering into a partnership with Biogen in 2007, the company granted Biogen the license to further develop and commercialize the treatment.

List of related literature:

This herbal extract has been approved in Germany for the treatment of dementia, and research in the United States has demonstrated no worsening of cognition in patients with Alzheimer’s disease who have taken it.

“Textbook of Family Medicine E-Book” by Robert E. Rakel
from Textbook of Family Medicine E-Book
by Robert E. Rakel
Elsevier Health Sciences, 2007

Another cholinesterase inhibitor, rivastigmine (Exelon), was approved (in 2000) for the treatment of dementia.

“Manual of Clinical Psychopharmacology” by Alan F. Schatzberg M.D., Charles DeBattista D.M.H. M.D.
from Manual of Clinical Psychopharmacology
by Alan F. Schatzberg M.D., Charles DeBattista D.M.H. M.D.
American Psychiatric Association Publishing, 2015

If you take a cholinesterase inhibitor like donepezil (Aricept), rivastigmine (Exelon), or galantamine (Razadyne)—which are all used to prevent or manage Alzheimer’s—the Alzheimer’s Association officially recommends not taking huperzine.

“Boundless: Upgrade Your Brain, Optimize Your Body & Defy Aging” by Ben Greenfield
from Boundless: Upgrade Your Brain, Optimize Your Body & Defy Aging
by Ben Greenfield
Victory Belt Publishing, 2020

Like donepezil, galantamine is postulated to slow the progression of Alzheimer’s dementia and has been shown to be effective in trials over a 1-year period.

“Handbook of Psychiatric Drug Therapy” by Lawrence A. Labbate, Jerrold F. Rosenbaum
from Handbook of Psychiatric Drug Therapy
by Lawrence A. Labbate, Jerrold F. Rosenbaum
Wolters Kluwer Health/Lippincott Williams & Wilkins, 2010

A meta-analysis of various drugs approved for treating Alzheimer’s disease in the USA and Canada has suggested that donepezil can delay cognitive impairment and deterioration in global health for at least 6 months in patients with mild-tomoderate Alzheimer’s disease (16).

“Meyler's Side Effects of Drugs 15E: The International Encyclopedia of Adverse Drug Reactions and Interactions” by Jeffrey K. Aronson
from Meyler’s Side Effects of Drugs 15E: The International Encyclopedia of Adverse Drug Reactions and Interactions
by Jeffrey K. Aronson
Elsevier Science, 2014

Alexia Lewis RD

Registered Dietitian Nutritionist and Certified Heath Coach who believes life is better with science, humor, and beautiful, delicious, healthy food.

[email protected]

View all posts

12 comments

Your email address will not be published. Required fields are marked *

  • Can’t come soon enough. 50 yr old woman with Apoe 4/4 trying to avoid Alzheimer’s with keto diet and exercise. For more info and support related to this genetic variant: apoe4.info

  • hey man, you’ve got it. get in touch with Prof. Bredesen. no you’ll NEVER have a BLOCK BUSTER Drug bc AD is a multi factorial disease and, therefore, needs an equivalent dynamic approach to treat it end of. the nutrition/lifestyle approach makes a lot of sense.

  • Jeff, I appreciate you sharing your experience with this trial and your true belief that this drug added a benefit to your cognitive abilities. Seems it is a subset of patients that responded and may not be enough to approve the drug but your testimony, along with others, adds to the need for further investigation…. timing of treatment and dosing? Lets answer these questions! Thank you for your participation in answering these questions to get closer to a treatment for this that so many of out loved ones are living with. My best to you and your wife!!!!

  • if the approvla will ad 50 billion market cap to biogen, it will also ad these ammount to EISAI. eisai now worth 14 billion, biogen 54 billion. so the right play now is to buy eisai which market cap could go x4 and it gives divident. biogen dont gives. my opinion

  • LOL!! This is just all about getting approval fast…… and recovering the huge capital expenditure invested in the R&D…… before China’s discovery is adopted worldwide. Chinese scientists announced a new treatment regime with a new drug made from seaweed just about 3 to 4 days ago. The Chinese initiative was touted as the first new drug introduced to treat Alzheimer’s Disease in 17 years.

  • LOVE your research Max… as a daughter of an ALZ parent I cannot thank you enough!! I watch ALL THE TIME>…. I truly believe this is a sugar based disease!!!!!!

  • Cassava sciences cracked the code already. They also finished their phase 2b trial, ready to publish the trial on march 2020. Insiders were confident for buying massive amounts of shares during december 2019. Market cap will be atleast 7 billion by fda approval alone, with buyout offer its 10 billion.

  • A ‘cure’ or treatment, help with prevention…something-just can’t come soon enough. Thanks Max for sharing what at least might be a glimmer of…hope?

  • This news is so encouraging; let’s hope the FDA gives approval and more patients with Alzheimer’s can be helped. More information is provided in this article: https://www.responsive-homecare.com/promising-alzheimers-disease-drug/

  • I am actually disappointed that they didn’t send a letter to inform the clinical trial participants about its cancellation they could have just wrote and sent a template letter or called each patient after all they helped Biogen so much

  • The FDA will approve plutonium pacifiers if the lobbying money is right. In the 60s there was a heroic lady director who refused to release Thalidomide in the US. The last FDA warrior for humanity.

  • Finally, some hopeful news in Alzheimer’s treatment options! This article shares more details about these findings: https://www.responsive-homecare.com/promising-alzheimers-disease-drug/